A recent study of patients with solid tumours treated with immune checkpoint inhibitors has shown improved overall survival in patients who had mutations in the genes that code for a group of proteins involved in the way DNA is packaged in the cell (SWI and SNF genes, BRG1/hBRM-associated factor (BAF) and polybromo-BAF (PBAF)).

The researchers suggest that while these results suggest a relationship between mutations in key genes coding for the PBAF and BAF groups of proteins and improved overall survival in patients with renal cell carcinoma (RCC) on immune checkpoint inhibitors, “there is a need for more work to discern the biology of mSWI/SNF and its interaction with checkpoint inhibitors.”

This research was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago at the beginning of this month.

Read more in Cancer Therapy Advisor here